Paragraf acquires Cardea Bio the technology platform developer of the CRISPR Chip graphene based biosensor that powers CRISPR QC’s CRISPR Analytics Platform. Paragraf is the only company
Source link
-
Paragraf acquires Cardea Bio the technology platform developer of the CRISPR Chip graphene based biosensor that powers CRISPR QC’s CRISPR Analytics Platform. Paragraf is the only company
Source link